Reference: Jew S, et al. Target Oncol. 2023;doi:10.1007/s11523-023-00990-6 - James R. Berenson, MD Berenson Cancer...
Press Release
American Society of Hematology
Blood Journal: A Phase 1 Trial: Evaluating…Methylprednisolone: RE: ASH 2023 San Diego, CA December 9-11 Media...
MedPage Today
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience with ruxolitinib suggests...
HemOnc Today
Multiple Myeloma regimens significantly less effective in real-world treatment settings In this study, researchers...
Healio Hematology & Oncology News
Healio Hematology & Oncology News: Interviewed Dr. Berenson on his perspective on Abstract 1 & Abstract 2....
HealthTree Foundation
Has built many patient programs and over 8 integrated software platforms to help blood cancer patients learn more...
Outcomes of Triple Class Refractory Multiple Myeloma Patients
| James Berenson, MD | ASH 2023 - video
Assessing Lenalidomide with Patients Progressing on JAK Inhibitors
| James Berenson, MD | ASH 2023 video
JAK inhibitors Transcript
So, we've been working on this class of drugs [JAK inhibitors] now for about 5 or 6 years, both in our research...
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest...
IMBCR & Emory University’s Big Discovery!!!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against...
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative LOS ANGELES, Nov....
What is Multiple Myeloma?
Survival and treatments are improving for this type of blood cancer You don't expect to break a rib while doing light...
Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated...
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M....
Outcomes in Multiple Myeloma Patients Evaluated
There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study...
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
Ariana Berenson Suzie Vardanyan Michael David James Wang Nika Manik Harutyunyan Jillian Gottlieb Ran Halleluyan...
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian...
Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients
Abstract Multiple myeloma (MM) is characterized by the enhanced production of the same monoclonal immunoglobulin (M-Ig...
A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma
Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with...
Results of CHAMPION-1: A Phase 1/2 Study of Weekly Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian,...
Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy
J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8,...
Advances in the Management of Multiple Myeloma
James R Berenson, MD, Tanya M Spektor, PhD, and James Wang Institute for Myeloma & Bone Cancer Research; James R...
To Transplant or Not To Transplant in Multiple Myeloma
Clinical Advances in Hematology & Oncology [button style="download"...
I Have WHAT? An Interview With Patient Advocate Debra Berenson
Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and author of the...
KIIS Cares Interview
What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the cells that make your blood, your red...
Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?
By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable...
Talking About Myeloma with Loved Ones
Do you feel the Love? The New Year is here. Perhaps you have been newly diagnosed? Whether a Myeloma warrior, or new...
Tommy Garceau, IMBCR’s Marathon Team Captain
Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for athletics and training. In July...
ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma
Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the...
An Overview of Progress in Myeloma Research with Dr. James Berenson
Myeloma news from the 2014 annual meeting of the American Society of Clinical Oncology has included updates on...
Multiple Myeloma: ‘Old Rules’ No Longer Apply
Original Article Writen by: Robert Carlson - Oncology Times NEW YORK—Treatment regimens for relapsed/refractory...
Counterpoints: To Transplant or Not To Transplant
More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common...
Tom Brokaw Bravely Facing Cancer Diagnosis
ORIGINAL STORY: Click Here. INSIDE EDITION: Airdate: 02/12/2014 There is an outpouring of support for legendary...
NBC News Special Correspondent Tom Brokaw
In response to NBC News Special Correspondent Tom Brokaw’s announcement that he has been diagnosed with multiple...
Is Treating Myeloma A Marathon or a Sprint?
Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, discusses the importance of weighing...
Several MAJOR new items have emerged from recent research efforts at IMBCR
First, we have uncovered a new serum marker for multiple myeloma which is a protein called B-cell maturation antigen...
Targeted Myeloma Treatments Bring Hope for Fewer Side Effects and Curative Therapy
Dr. James Berenson discusses the importance of using maintenance therapies with limited short- or long-term side...
Experts Disagree on Role of Transplant in Myeloma
New drugs provide powerful options, but little consensus on standard treatments New York—There is a profound...
Multiple Myeloma Survival Increased Significantly The Past 15 Years, But Unevenly Across Ethnic And Age Groups
Posted By Navneet Ramesh and Maike Haehle on the Myeloma Beacon on Aug 31, 2013 2:01 Researchers recently reported...
The Institute for Myeloma & Bone Cancer Research is an official charity of the 2014 ASICS LA Marathon
The Institute for Myeloma & Bone Cancer Research (IMBCR) is proud to announce that it is an official charity of...
What’s New in Myeloma?
There have been several recent breakthroughs for the treatment of multiple myeloma patients that have led to new...
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Berenson JR, Yellin O, Bessudo A,...
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17. Sanchez E, Li M, Li J, Wang C,...
Myeloma Cure Panel Broadcast – Dr. James Berenson will discuss Multiple Myeloma disease control Without Transplant
Dr. Berenson will be the featured Myeloma Cure Talk Panel member on this November 29th, 2012 @ 6:00 PM EST broadcast. ...
Updates in the Treatment of Multiple Myeloma
Updates in the Treatment of Multiple Myeloma (PDF)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. Sanchez E, Li M, Kitto...
Dedication of “Determination”
The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication of a newly designed...
Understanding Myeloma News About Secondary Cancers and Clotting
Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and...
Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and...
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg J,...
Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
The results of this landmark study should be welcomed news to cancer patients across the world suffering from the...